Nexipraz Otc 30 mg Gastric-resistant tablets
PDF Leaflet Revision Date: 07 August 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Temporary relief of heartburn and hyperacidity.
Dosage (summary)
20 mg (one tablet) daily for a maximum of 14 days.
Onset of Action / Duration
Onset: 1 hour, Duration: up to 24 hours.
Special Populations
- Impaired renal function
- Impaired hepatic function
- Elderly
Pregnancy & Breastfeeding
Safety not established during pregnancy and breastfeeding.
Key Drug Interactions
- Atazanavir
- Nelfinavir
- Clopidogrel
- Methotrexate
- Tacrolimus
Contraindications
- Hypersensitivity to esomeprazole
- Co-administration with atazanavir and nelfinavir
Common side effects
- Headache
- Abdominal pain
- Diarrhoea
- Nausea
Counselling Points
- Do not chew or crush tablets.
- Consult doctor if no relief after 14 days.
- Avoid long-term use without medical advice.
Serious warnings
- Risk of gastric infections
- Potential for SCLE
- Consult doctor for significant weight loss or recurrent vomiting
Important Disclaimer
The Nexipraz Otc 30 mg Gastric-resistant tablets professional information leaflet below is the property of Ranbaxy Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
